National Bank of Canada
RCKT icon

National Bank of Canada’s Rocket Pharmaceuticals RCKT Stock Holding History

National Bank of Canada’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-900
Closed -$3.21K – 3304
2026
Q1 		$3.21K Buy
+900
New +$3.58K ﹤0.01% 2541
2025
Q2 		– Sell
-100
Closed -$664 – 3187
2025
Q1 		$664 Buy
100
+30
+43% +$296 ﹤0.01% 2616
2024
Q4 		$880 Hold
70
– – ﹤0.01% 2661
2024
Q3 		$1.29K Buy
70
+35
+100% +$717 ﹤0.01% 2404
2024
Q2 		$720 Buy
+35
New +$804 ﹤0.01% 2531

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

National Bank of Canada's RCKT Position: Q2 2026 in Review

National Bank of Canada sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 900 shares — an estimated $3.21K sold.

National Bank of Canada first reported a position in RCKT in Q2 2024 and held it in 5 quarters. The position peaked at $3.21K in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • National Bank of Canada reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • National Bank of Canada sold 900 Rocket Pharmaceuticals shares in Q2 2026, an estimated $3.21K.
  • National Bank of Canada first reported a position in Rocket Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • National Bank of Canada's Rocket Pharmaceuticals position peaked at $3.21K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.